Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea

Clinical Microbiology and Infection

Volumn 19, Issue 6, 2013, Pages 521-527

  Kim, J ^a   Kang, J O ^a   Kim, H ^b   Seo, M R ^a   Choi, T Y ^a   Pai, H ^a   Kuijper, E J ^c   Sanders, I ^c   Fawley, W ^d  

^a Hanyang University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Antibiotic usage; Clostridium difficile; Epidemiology; Hospital acquired infection; Ribotype

Indexed keywords

BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; GLYCOPEPTIDE; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE CONTROL; HOSPITAL DEPARTMENT; HUMAN; INCIDENCE; INFORMATION PROCESSING; KOREA; MAJOR CLINICAL STUDY; OCCUPATIONAL DISEASE; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; WARD;

CLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HOSPITAL UNITS; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RIBOTYPING; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 84876786251     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03910.x     Document Type: Article

References (29)

1. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al.The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-549.
2. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007; 35: 300-307.
3. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45: 1543-1549.
4. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990; 11: 283-290.
5. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
6. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
7. Chung CH, Wu CJ, Lee HC, Yan JJ, Chang CM, Lee NY, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect 2010; 43: 119-125.
8. Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci 2011; 26: 1258-1264.
9. Sawabe E, Kato H, Osawa K, Chida T, Tojo N, Arakawa Y, et al.Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 2007; 26: 695-703.
10. Iwashima Y, Nakamura A, Kato H, Wakimoto Y, Wakiyama N, Kaji C, et al.A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother 2010; 16: 329-333.
11. Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 2008; 14: 1057-1064.
12. Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, McGeer A, et al.Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerg Infect Dis 2010; 16: 678-681.
13. Belmares J, Johnson S, Parada JP, Olson MM, Clabots CR, Bettin KM, et al.Molecular epidemiology of Clostridium difficile over the course of 10years in a tertiary care hospital. Clin Infect Dis 2009; 49: 1141-1147.
14. World Health Organization. The anatomical therapeutic chemical (ATC) and defined daily dosing (DDD) system index 2010. 2010; Available from: http://www.whocc.no/ (Accessed on 28 Oct 2010).
15. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999; 175: 261-266.
16. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-463.
17. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin MG, et al.Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 2010; 30: 491-497.
18. Solomon K, Fanning S, McDermott S, Murray S, Scott L, Martin A, et al.PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. J Antimicrob Chemother 2011; 66: 1976-1982.
19. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of Anaerobic bacteria, Approved standard 7th edn. CLSI document M11-A7; Wayne, PA: CLSI, 2007.
20. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, et al.Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 2009; 15: 230-233.
21. Lyerly DM, Neville LM, Evans DT, Fill J, Allen S, Greene W, et al.Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol 1998; 36: 184-190.
22. Kim H, Riley TV, Kim M, Kim CK, Yong D, Lee K, et al.Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis. J Clin Microbiol 2008; 46: 1116-1117.
23. Komatsu M, Kato H, Aihara M, Shimakawa K, Iwasaki M, Nagasaka Y, et al.High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003; 22: 525-529.
24. Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G. Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill 2009; 14: 19403.
25. Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, et al.Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2706-2714.
26. Goorhuis A, Debast SB, Dutilh JC, van Kinschot CM, Harmanus C, Cannegieter SC, et al.Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis 2011; 53: 860-869.
27. Taori SK, Hall V, Poxton IR. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 2010; 59: 338-344.
28. Zaiss NH, Witte W, Nubel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010; 16: 675-677.
29. Aldeyab MA, Devine MJ, Flanagan P, Mannion M, Craig A, Scott MG, et al.Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures. Infect Control Hosp Epidemiol 2011; 32: 210-219.